Trastuzumab deruxtecan
Pre-clinicalRecruiting 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-positive Breast Cancer
Conditions
HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer
Trial Timeline
Jan 15, 2024 โ Mar 1, 2028
NCT ID
NCT06210776About Trastuzumab deruxtecan
Trastuzumab deruxtecan is a pre-clinical stage product being developed by Daiichi Sankyo for HER2-positive Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06210776. Target conditions include HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07015697 | Phase 1 | Recruiting |
| NCT06750484 | Phase 2 | Recruiting |
| NCT05982678 | Phase 2 | Recruiting |
| NCT06386263 | Pre-clinical | Completed |
| NCT06210776 | Pre-clinical | Recruiting |
| NCT05950945 | Phase 3 | Recruiting |
| NCT05993234 | Pre-clinical | Recruiting |
| NCT05945732 | Pre-clinical | Recruiting |
| NCT05458401 | Pre-clinical | Completed |
| NCT05246514 | Phase 2 | Active |
| NCT04989816 | Phase 2 | Completed |
| NCT04739761 | Phase 3 | Active |
| NCT04644237 | Phase 2 | Completed |
| NCT04639219 | Phase 2 | Active |
| NCT04482309 | Phase 2 | Recruiting |
| NCT04752059 | Phase 2 | Completed |
| NCT04420598 | Phase 2 | Completed |
| NCT04014075 | Phase 2 | Completed |
| NCT03505710 | Phase 2 | Terminated |
Competing Products
20 competing products in HER2-positive Breast Cancer